imipramine has been researched along with Non-alcoholic Fatty Liver Disease in 2 studies
Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, X | 1 |
| Hou, S | 1 |
| Xiang, R | 1 |
| Hu, C | 1 |
| Chen, Z | 1 |
| Li, N | 1 |
| Yan, H | 1 |
| Yu, X | 1 |
| Li, X | 1 |
| Chi, Y | 1 |
| Yang, J | 1 |
| Lu, Z | 1 |
| Li, Y | 1 |
| Chowdhury, N | 1 |
| Yu, H | 1 |
| Syn, WK | 1 |
| Lopes-Virella, M | 1 |
| Yilmaz, Ö | 1 |
| Huang, Y | 1 |
2 other studies available for imipramine and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis.
Topics: Adenosine Triphosphate; Animals; Calmodulin; Carnitine O-Palmitoyltransferase; Cytokines; Diet, High | 2022 |
The Presence of Periodontitis Exacerbates Non-Alcoholic Fatty Liver Disease via Sphingolipid Metabolism-Associated Insulin Resistance and Hepatic Inflammation in Mice with Metabolic Syndrome.
Topics: Animals; Ceramides; Diet, High-Fat; Imipramine; Inflammation; Insulin Resistance; Lipopolysaccharide | 2023 |